229 patents
Page 7 of 12
Utility
Compounds Useful As Chaperone-mediated Autophagy Modulators
14 Oct 21
Ana Maria CUERVO, Evripidis GAVATHIOTIS
Filed: 30 Aug 18
Utility
Microbial hyperswarmers and uses thereof
12 Oct 21
Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis of conditions such as intestinal inflammation.
Sridhar Mani, Libusha Kelly, Hao Li
Filed: 10 Sep 20
Utility
Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins
5 Oct 21
Methods for treating and for preventing filovirus infections are disclosed, as well as compositions therefor.
Jonathan R. Lai, Julia Frei, Elisabeth Nyakatura
Filed: 22 Aug 19
Utility
Peptides for blocking IL1RAP protein-protein interaction and uses thereof for treatment of disease
5 Oct 21
Methods and agents are provided for inhibiting interleukin 1 receptor accessory protein (IL1RAP) protein-protein interaction to treat a broad spectrum of diseases and conditions.
Ulrich Steidl, Laura Barreyro De Pujato, Mario Pujato
Filed: 23 Nov 15
Utility
Filovirus Antibody
23 Sep 21
The present invention addresses a need for antibodies useful for filovirus infections.
Jonathan R. Lai, Jayne F.. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
Filed: 28 Dec 20
Utility
Persistance and Linking of Analytic Products In Big Data Environments
23 Sep 21
Persistence and linking of analytic products is provided.
Parsa Mirhaji, Jannes Aasman
Filed: 14 Jul 17
Utility
DNA methyltransferase 1 transition state structure and uses thereof
7 Sep 21
Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.
Vern L. Schramm, Quan Du, Zhen Wang
Filed: 13 Feb 18
Utility
Low Intensity Focused Ultrasound for Treating Cancer and Metastasis
2 Sep 21
Systems and methods for treating cancer and for preventing metastasis using low intensity focused ultrasound in combination with an anti-cancer therapy are disclosed.
Chandan GUHA, Stephen BARRY, Fernando MACIAN
Filed: 3 Mar 21
Utility
Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
24 Aug 21
Emily H. Cheng, Paul Jeng, Ouathek Ouerfelli, James Hsieh, Guangli Yang, Evripidis Gavathiotis
Filed: 12 Aug 16
Utility
Host and intestinal microbiota derived metabolomic blood plasma signature for prior radiation injury
17 Aug 21
Provided are methods of determining prior radiation dose exposure levels for subjects, and kits therefor.
Aaron Alain-Jon Golden, Pilib Ó Broin, Chandan Guha, Irwin Kurland
Filed: 13 Nov 15
Utility
Tmem-mcd In the Minimally Invasive Assessment of the Activity Status of Tmem In Its Dissemination of Tumor Cells
12 Aug 21
Methods are provided for measuring the activity of TMEM sites in a tumor comprising measuring a transient increase in permeability of blood vessels at TMEM sites that allows tumor cells to enter the blood vessels, wherein permeability is measured using a modality selected from the group consisting of MRI, PET, CT, and SPECT, and wherein a transient increase in permeability indicates that a TMEM site is active.
John CONDEELIS, Craig BRANCH, Maja OKTAY
Filed: 12 Jun 19
Utility
HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE
5 Aug 21
Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, compositions and vaccines comprising such, and methods of use thereof are each provided.
William Jacobs, Jr., Betsy Herold, Joseph Dardick, Kayla A. Weiss
Filed: 1 May 19
Utility
Syntac Polypeptides and Uses Thereof
5 Aug 21
Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.
Ronald D. Seidel, III, Rodolfo J. Chaparro, Brandan S. Hillerich, Scott J. Garforth, Steven C. Almo
Filed: 25 Aug 20
Utility
Tmem Active Test and Uses Thereof In Diagnosis, Prognosis and Treatment of Tumors
22 Jul 21
Disclosed are kits and methods for detecting the presence of tumor sites that are active in tumor cell dissemination and uses thereof for determining the risk of tumor cells undergoing hematogenous metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, for determining a course of treatment for a localized tumor, and for identifying agents to treat or prevent hematogenous metastasis.
John S. Condeelis, Allison S. Harney
Filed: 23 Mar 21
Utility
PAK1 inhibitors and uses thereof
20 Jul 21
Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using compounds that inhibit p21 protein (Cdc42/Rac)-activated kinase (PAK1).
Ulrich Steidl, Ashley M. Eckel, Robert F. Stanley, Boris Rogovoy, Ilya Okun
Filed: 3 Apr 17
Utility
Method of ameliorating side effects of sickle cell disease treatments
20 Jul 21
A method of reducing a cerebral tissue pathology associated with a sickle cell disease therapy in a subject is provided using (i) a synthetic high-oxygen affinity hemoglobin-containing molecule or (ii) synthetically treated high-oxygen affinity blood.
Craig Branch, Seetharama Acharya
Filed: 8 Nov 16
Utility
Oral administration of melanin for protection against radiation
13 Jul 21
Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation.
Ekaterina Dadachova, Arturo Casadevall
Filed: 6 Jun 19
Utility
Rictor-targeted Therapy In the Management of Brain Metastases
8 Jul 21
A method of treating metastases (e.g., brain metastases) in a patient with cancer (e.g., lung cancer) and at risk for metastases, exhibiting symptoms of metastases, or identified with metastases includes administering a therapeutically effective amount of a RICTOR inhibitor for the treatment of metastases.
Haiying Cheng, Roman Perez-Soler, Balazs Halmos, Ni Fan, Yiyu Zou
Filed: 8 Jan 21
Utility
Inhibitors of DNMT1 As Anticancer Therapeutic Agents
8 Jul 21
Peter Charles Tyler, Farah Lamiable-Oulaidi, Anthony David Woolhouse, Shivali Ashwin Gulab, Karl Jürgen Shaffer, Ashna Ashneen Khan, Douglas Ronald Crump, Vern L. Schramm, Quan Du
Filed: 9 Jul 19
Utility
Monoclonal Antibodies Against Human TIM-3
1 Jul 21
Provided are anti-human Tim-3 IgV domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.
Xingxing ZANG
Filed: 21 Aug 19